Abcam, ab265484, Human ADAM9 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
ADAM9 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ADAM9, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ADAM9 also known as Meltrin gamma is a member of the ADAM (a disintegrin and metalloproteinase) family characterized by both proteolytic and adhesive properties. The ADAM9 protein weighs approximately 84 kDa and is expressed in various tissues including the brain throat and lungs. It plays an important role in cellular processes such as cell-cell and cell-matrix interactions due to its disintegrin domain.
Biological function summary
ADAM9 participates in numerous essential cellular functions particularly in cell surface protein shedding and proteolytic activities. It is part of the protease complex involved in shedding epidermal growth factor receptor (EGFR) ligands. This action impacts cell signaling pathways that contribute to processes such as cell proliferation migration and invasion.
Pathways
Many studies link ADAM9 to pathways involving cell signal modulation and extracellular matrix remodeling. It participates in the EGFR signaling pathway significantly affecting cell behavior. ADAM9 interacts with other proteins such as integrins which facilitate changes in cell dynamics and communication.
Evidence implicates ADAM9 in several cancers including breast cancer and prostate cancer. It plays a role in cancer development by promoting cell invasion and metastasis. ADAM9 is also associated with Alzheimer's disease through interactions with proteins like APP (amyloid precursor protein) suggesting its involvement in neuronal degradation and plaque formation.